



2025

ANNUAL REPORT

2025

TABLE OF CONTENTS

Presidents' report	3
Governance and structure	7
Committees and SIGs	11
Our members	12
Financial report	17
Equality and diversity	19
Legal status	
Articles and rules	



The UK Kidney Association
Brandon House, Building 20A1
Southmead Road
Bristol
BS34 7RR



ukka@ukkidney.org



ukkidney.org

PRESIDENTS' REPORT

LOOKING BACK ON 2025

A Year of Delivery, Collaboration and Impact

As we reflect on 2025, we would like to begin by thanking the entire kidney community. First and foremost, we recognise the extraordinary work undertaken every day across clinical and academic kidney centres, networks and community services. The commitment, expertise and compassion of multi-professional teams continue to make a profound difference to the patients and families we collectively serve.

We are also deeply grateful to the many individuals who contribute directly to the work of the UK Kidney Association. Whether leading or participating in a Special Interest Group, serving on a Committee, shaping quality improvement initiatives, contributing to guideline development, supporting the Registries, or planning and delivering UK Kidney Week, your voluntary commitment is the foundation of our success as a professional association.

We would like to acknowledge the dedication of our Secretariat and Business Operations Teams, whose expertise and organisational leadership enable the breadth of projects delivered across the year.

Our Kidney Quality Improvement Partnership (KQIP) has continued to lead major national initiatives alongside local improvement collaboratives. Working closely with our Patient Council, the team has ensured that the patient voice remains central - including through the Kidney PREM report and contributions to data governance and service improvement.


Our Registries - the UK Renal Registry (UKRR) and RaDaR - remain internationally recognised assets, underpinning research, service planning and quality assurance across the UK.

Professional Groups and Strategic Partnerships

Our professional groups remain the heart of the Association. Their leadership across education, research, service transformation and policy continues to strengthen UK nephrology.

We are particularly pleased to be in advanced discussions with the Association of Nephrology Nurses UK (ANN UK) regarding plans to unite our organisations by the end of 2026, strengthening multidisciplinary collaboration across the kidney workforce.

During 2025, we also established closer working relationships with the British and Irish Hypertension Society, the Primary Care Cardiovascular Society, and the Primary Care Diabetes Society. In an increasingly complex and comorbid specialty, these partnerships allow us to align advocacy, share learning and improve outcomes for shared patient populations. The establishment of the Renal Manager Professional Group marks an important step in recognising the critical contribution of non-clinical leadership to service delivery and implementation.



Governance and Leadership

On a personal note, we extend sincere thanks to our Chief Executive and Trustees for their commitment and stewardship.

In particular, we acknowledge the contributions of our retiring trustees:

- Alan Salama, who stepped down as Secretary after providing exceptional leadership during and following the merger of the Renal Association and the British Renal Society. His work strengthened governance, communication and academic strategy across the Association.
- Paul Cockwell, who concluded his service after terms as Clinical Vice President and President. He played a central role in delivering the merger, guiding the Association through the COVID-19 period, establishing many of the structures that underpin our current success, and championing excellence across both clinical and academic nephrology, particularly in the chronic kidney disease space.

We were delighted to welcome Linda Tarm and Bhavna Pandya as new trustees, supporting professional groups alongside leadership and policy development.

75th Anniversary

2025 marked the 75th anniversary of the UK Kidney Association - a landmark year for the world's oldest continuously active nephrology society. The anniversary programme reflected both our history and our future, with year-long themed activity highlighting members, professional groups and key milestones in UK kidney care. It reinforced the UKKA's enduring role in connecting professionals, advancing standards and supporting better kidney care for all.

Clinical Impact

During 2025 we:

- Delivered multiple national clinical guidelines
 - Management of blood pressure in adults, children and young people on dialysis
 - Anticoagulation for venous thromboembolism in adults with advanced kidney disease
 - Anticoagulation for atrial fibrillation in adults with advanced kidney disease
 - The initial immunosuppressive treatment for children and young people with immune-mediated glomerular diseases
- Appointed two CKD champions to develop educational resources, map improvement initiatives nationally, and scale progress in early-stage kidney disease.
- Continued KQIP programmes across five sites, focusing on advanced kidney care, while hosting national engagement events, including those focused on lived experience.
- Expanded our home therapies work, addressing home haemodialysis, peritoneal dialysis and supported self-care within units.
- Established new Special Interest Groups on In-Centre Haemodialysis and Glomerulonephritis (GN).
- Continued to expand the Renal Drug Database, now exceeding 1,050 monographs, supported by an Editor-in-Chief and an active reviewer network within the UK RPG. The sixth printed edition is in preparation.

Leadership and Advocacy

In partnership with kidney charities, we engaged UK policymakers to support the recognition of CKD within the WHO framework of major non-communicable diseases. We also submitted detailed recommendations to inform the Government's development of the 10-Year Health Plan, outlining the future kidney workforce and service configuration.

Late in the year, we launched the "Voices to Vision" campaign, highlighting the 7 million people affected by kidney disease across the UK. A joint working group spanning all four nations presented a letter to 10 Downing Street, signed by over 13,000 supporters, advocating for greater national focus on kidney health.

We published our latest workforce report and recruited the second cohort of our Leadership Programme, with 27 participants undertaking structured learning and applied project work to develop future leaders in nephrology.

Research and Data

The Renal Laboratory Scientists Group continues to grow in scale and influence. Education in research methodology was embedded as a key theme for UK Kidney Week 2026, and collaboration between Special Interest Groups and Clinical Study Groups is being refreshed to ensure alignment and minimise duplication.

The UKRR has accelerated reporting timelines, with 20% of units now submitting daily data and a target of generating analytical outputs within three months of submission.

RaDaR continues to lead internationally in rare kidney disease data collection and was invited to present its work to the U.S. Food and Drug Administration.

We are exploring the expansion of GN data capture within the UKRR dataset, working closely with the GN Community of Practice and Clinical Study Group to support equitable access to optimal care across the UK.

Education

This year marked the launch of our Education Hub, significantly expanding access to high-quality professional learning resources across the kidney community.

We delivered 22 face-to-face meetings, engaging more than 2,000 participants. In addition, we hosted five webinars, including sessions led by the Renal SpR Club, which provided timely updates to the multi-professional workforce on rapidly evolving therapies, including developments in IgA nephropathy.

New educational packages were developed in:

- Acute Kidney Injury
- Chronic Kidney Disease for primary care pharmacists
- Advanced pharmacy practice

UK Kidney Week in Bournemouth welcomed 1,220 delegates, reflecting strong engagement across the sector. Preparations are already well underway for the forthcoming meeting in Harrogate, which is being delivered within a compressed nine-month planning cycle.



Looking Ahead

This report provides only a snapshot of the breadth of activity delivered in 2025. We hope you will explore the full report to see the scale and impact of the Association's work - and perhaps be inspired to contribute to future initiatives.

As we prepare for UK Kidney Week 2026, we can be proud of what has been achieved together and equally energised by the challenges and opportunities ahead.

Thank you for your continued commitment to kidney care across the UK. We look forward to seeing many of you in Harrogate.



Clare Morlidge
President



Dr Katie Vinen
President

GOVERNANCE AND STRUCTURE

The board of trustees is the UK Kidney Association's governing body as a charity. It is responsible for the management of the UK Kidney Association's business, for which purpose they may exercise all the powers of the UK Kidney Association. The board meets face to face at least three times a year to:

- Manage risk
- Oversee strategy, define policy, agree the business plan and monitor progress
- Ensure the proper management of the assets of the Renal Association (trading as the UK Kidney Association) for the benefit of the objects.

It has the authority to carry out the charitable responsibilities of the UK Kidney Association and delegates the operational aspects of its affairs to its CEO and Committees. It works closely and liaises with the UK Kidney Association Professional Council but ultimately, all decisions (apart from changes to the Articles of Association) are either taken by, or on behalf of, the Board of Trustees and reported to the membership at the annual general meeting.

OUR TRUSTEES



PRESIDENT

Dr Katie Vinen

King's College Hospital



PRESIDENT

Clare Morlidge

Lister Hospital



PAST-PRESIDENT

Prof Paul Cockwell

*Queen Elizabeth
Hospital Birmingham*



BAPN PRESIDENT

Prof Stephen Marks

*Great Ormond Street
Hospital*



PRESIDENT-ELECT

Lisa Ancliffe

Royal Free London

OUR TRUSTEES - 2025



**HONORARY
MEMBERSHIP &
POLICY SECRETARY**

Prof Alan Salama
*Royal Free Hospital
London*



**HONORARY
MEMBERSHIP &
POLICY SECRETARY**

Linda Tarm
*London Kidney
Network*



**CLINICAL VICE
PRESIDENT**

Prof James Burton
University of Leicester



**CLINICAL VICE
PRESIDENT**

Lisa Ancliffe
Royal Free London



**ACADEMIC VICE
PRESIDENT**

Prof John Sayer
Newcastle University



**ACADEMIC VICE
PRESIDENT**

Kathrine Parker
*Manchester University
Hospitals*



**NON-MEMBER
TRUSTEE**

Laura Meaden



**NON-MEMBER
TRUSTEE**

Mark Froud



**TRUSTEE WITH
FINANCIAL
GOVERNANCE
RESPONSIBILITY**

Prof Timothy Bowen
Cardiff University

SENIOR MANAGEMENT TEAM



CEO

Ron Cullen



**DIRECTOR OF
INFORMATICS
RESEARCH**

Professor
Dorothea Nitsch



**UKRR MEDICAL
DIRECTOR**

Professor James
Medcalf



**UKRR HEAD OF
OPERATIONS**

Dr Retha
Steenkamp





**HEAD OF
FINANCE &
BUSINESS
DEVELOPMENT**


Stephanie Lock



STRUCTURE



FOUR PILLARS OF THE UKKA



COMMITTEES & SPECIAL INTEREST GROUPS

Clinical and Academic Committees continue to meet the needs of UK Kidney Association members. Central to delivery, the UKKA is focused on the creation of a series of multi-professional Special Interest Groups (SIGs) supported and enabled through core UKKA corporate structures.



Committees & Chairs

- Clinical Practice Guidelines Committee - Dr Mark Devonald & Andrea Devaney
- International Committee - Prof Sunil Bhandari (incoming Dr Yusuf Jinadu)
- Clinical Services Committee - Dr Marie Condon
- Education and Training Committee - Prof Debasish Banerjee (incoming Dr Shalabh Srivastava)
- Patient Safety Committee - Dr Katrin Jones & Karen Jenkins
- Patient Information Committee - Dr Vincent Tse & Laurie Cuthbert
- Sustainable Kidney Care Committee - Dr Suren Kanagasundaram & Gloria Muñoz Figueroa
- Rare Diseases Committee - Prof Danny Gale
- Ethics and Law Committee - Dr Jordan Parsons & Dr Ben Thomas

Special Interest Groups & chairs


- Acute Kidney Injury - Dr Jon Murray & Clare Morlidge
- Chronic Kidney Disease - Prof Paul Cockwell (incoming Dr Gavin Dreyer)
- Diagnostic Interventional Nephrology - Dr Saeed Ahmed
- Home Dialysis - Dr Mark Lambie & Stephanie Walker
- Living Well With Kidney Disease - Dr Rosa Montero & Helena Jackson
- Supportive Care - Karen Jenkins & Dr Jyoti Baharani
- Transition to Young Adult - Dr Arvind Nagra & Hazel Gibson
- In-centre Haemodialysis - Dr Damian Ashby & Anil Permessur



OUR MEMBERS


In 2025, membership of the UKKA comprised over **1,946** doctors, scientists and MPT members.

Members based on job title



OUR MEMBERS

At the end of 2025, we moved to a new membership system, which makes it easier for members to manage their UK Kidney Association memberships, check details, register for events, and stay connected with their Committees, SIGs and Professional Groups.



Membership

Current Memberships

For any questions regarding your memberships please contact ukka@ukkidney.org

SALARY: UNDER £25,000 PER YEAR (#2107)

Payment method
Not selected

Status: Active Price: £15.00 RENEWS ON: 09/01/2027

[Change membership plan](#)

Membership settings

Renew automatically: Yes
Renewal price: £15.00

[MEMBERSHIP CARD](#)

[Membership Card Info](#)

Upcoming Events

Event Name From Date Until Date Event Type
Search events: dd/mm/yyyy dd/mm/yyyy Select event type: [v]
Reset filter

<p>UK Kidney Week 2026 Tue 10 Mar 09:00 - Thu 12 Mar 17:00</p>			
<p>Clinical Directors' Forum 2026 Mon 9 Mar 13:30 - 11:00</p>	<p>Paediatric Kidney Replacement Therapy Online Workshop - Peritoneal Dialysis Thu 16 Apr 13:00 - 17:00</p>	<p>SpR Spring Meeting 2026 - Newcastle Sat 25 Apr 12:00 - Sun 24 Apr 13:30</p>	

No. 800723 Registered office: The UK Kidney Association.

Professional Groups

Order by: [v]

<p>BAPN British Association for Paediatric Nephrology</p> <p>British Association for Paediatric Nephrology (BAPN) Professional group for those involved in the care of children and young people with kidney diseases.</p>	<p>CLINICAL DIRECTORS GROUP</p> <p>Clinical Director Group (CD Group) The UKKA Clinical Directors Group is a network of kidney service directors that enables sharing of expertise, discussion of service delivery challenges, and collaboration on strategies to improve patient care across the UK.</p>	<p>CLINICAL DIRECTORS GROUP</p> <p>Clinical Directors Steering Group The CD's Steering Group provides leadership and representation for the Clinical Director Group. The committee also oversees the CD Forum and communications to the CD Group.</p>
<p>KPT Kidney Psychological Therapists</p> <p>Kidney Psychological Therapists (KPT) Professional group for psychological therapists working with people with kidney disease.</p>	<p>Laboratory Scientists Group</p> <p>Laboratory Scientist Group (LSG) Professional group for laboratory scientists working in renal.</p>	<p>PNG Paediatric Nephrology Nurses Group</p> <p>Paediatric Nephrology Nurses Group (PNG) Professional group for paediatric nurses working in nephrology</p>
<p>PAWR Physical Activity, Wellbeing & Rehabilitation</p> <p>Physical Activity, Rehabilitation and Wellbeing Group (PAWR) Professional group for those working in physical activity, wellbeing, and rehabilitation for people with kidney disease.</p>	<p>UKRMG UK Renal Manager Group</p> <p>Renal Manager Group (UKRMG) Professional group for non-clinical renal managers and service leads</p>	<p>UK Renal Pathology Network</p> <p>UK Renal Pathology Network (UKRPN) Professional group for Renal Pathologists. A national network of pathologists, clinicians, and researchers focused on kidney disease.</p>

Groups

Clinical Practice Guideline Groups

Bring together UKKA members to develop evidence-based clinical guidance on specific topics, supporting safe, up-to-date care for people with kidney disease and helping professionals deliver high-quality practice.

Committees

Bring together UKKA members to collaborate on specialised functions that support kidney professionals. They play a vital role in shaping the organisation's direction, promoting best practice, and driving innovation across kidney care.

Professional Groups

Bring together UKKA members from the same profession to share expertise, network, develop standards and education, and ensure their profession is represented in organisational decisions.

Special Interest Groups (SIGs)

Bring together UKKA members in a specialty area of kidney care, supporting UK renal professionals in delivering best practice and effective leadership.

OUR MEMBERS

AWARDS, BURSARIES & LECTURES

Raine Award

This prestigious award is made to a relatively junior member who has made a significant contribution to research. In 2025, this was awarded to **Dr Omid Sadeghi-Alavijeh** at UK Kidney Week.

Stewart Cameron Lecture for Outstanding Contribution to the Basic Scientific Understanding of Kidney Disease

Established in memory of Professor Stewart Cameron and awarded to a non-clinical basic scientist whose work has contributed significantly to kidney disease research. In 2025, this lecture was delivered by **Dr Becky Foster** at UK Kidney Week.

The UKKA Lifetime Achievement Award

Honouring exceptional individuals who have left an indelible mark on the kidney community through their remarkable contributions to academic medicine, clinical care, education, and leadership. In 2025, this was awarded to **Dr Graham Lipkin** at UK Kidney Week.

O'Donoghue Lecture

This lecture is named in honour of the UKKA's former President, Professor Donal O'Donoghue OBE. In 2025, this lecture was delivered by **Professor David Wheeler** at UK Kidney Week.

Chandos Lecture

This lecture honours the Chandos family, who have given great support to the kidney community over many years. In 2025, this lecture was not awarded.

Donna Lamping Researcher Award

For outstanding research in Kidney Care. In 2025, this was awarded to **Dr Hannah Young** at UK Kidney Week.

Medical student elective bursaries

The UK Kidney Association awards 8 bursaries to medical students who are planning to undertake electives which include a significant renal component, either clinical or research. 8 bursaries were awarded in January 2025.

CONSULTATIONS

The UK Kidney Association has been involved in a number of consultations in the last year. Thank you to all members who contributed.

UK Kidney Association

- Technology Appraisal: Targeted-release budesonide for treating primary IgA nephropathy (ID6485) - **Chee Kay Cheung**
- Draft guidance to s/holders: Sparsentan for treating primary IgA nephropathy (ID6308) - **Jon Barratt**
- Single Technology Appraisal: Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over (ID6489) - **Edwin Wong**
- Single Technology Appraisal: Obinutuzumab with immunosuppressive therapies for treating lupus nephritis (ID6420) - **Ruth Pepper**
- Single Technology Appraisal: Iptacopan for treating complement 3 glomerulopathy (ID6283) - **Edwin Wong**
- Type 2 diabetes in adults: management (medicines update) - **Andrew Frankel/Rosa Montero** (joint ABCD/UKKA submission)
- Appraisal invitation: Cardiovascular events (major, prevention, overweight, obesity) - semaglutide (ID6441) - **Clare Morlidge**
- Single Technology Appraisal: Sodium zirconium cyclosilicate for the treatment of persistent hyperkalaemia (ID6439) - **Annette Alfonso**

UK Renal Pharmacy Group

- Single Technology Appraisal: Obinutuzumab for treating lupus nephritis (ID6420) - **Rachna Bedi**
- Appraisal Invitation: Glomerulopathy (complement 3) – iptacopan (ID6283) - **Robert Brown**
- Technology Appraisal: Targeted-release budesonide for treating primary IgA nephropathy (ID6485) - **Olivia Kanka**
- Technology Appraisal - draft guidance: Sparsentan for treating primary IgA nephropathy (ID6308) - **Dipesh Patel**
- Single Technology Appraisal: Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over (ID6489) - **Olivia Kanka**
- Single Technology Appraisal: Orforglipron for managing overweight and obesity (ID6516) - **Denise Cunningham**
- Type 2 diabetes in adults: management (medicines update) - **Ciara Doherty and Kiran Sanghera**
- Single Technology Appraisal: Palopegteriparatide for treating chronic hypoparathyroidism (ID6380) - **Marc Vincent**
- Single Technology Appraisal: Sodium zirconium cyclosilicate for the treatment of persistent hyperkalaemia (ID6439) - **Clare Morlidge**

FINANCIAL REPORT

Professor Timothy Bowen, Trustee with Financial Governance Responsibility

Mrs Stephanie Lock – Head of Finance

The UK Kidney Association (UKKA) reported an overall surplus of £856,112 for 2025 (2024: £509,294).

As the AGM is being held earlier than in previous years, these figures remain subject to year-end adjustments. All data has been provided by the UKKA; however, the interpretation and presentation are the responsibility of the author. The figures are currently unaudited and may change ahead of the publication of the final statutory accounts, expected by September 2026 on the Companies House website.

Since taking up the position of UKKA Trustee with Financial Responsibility in June 2023, my priority has been to ensure that the charity has financial stability and is a going concern for the future. This has been achieved for 2025, and I am satisfied that we have operated with good governance, as well as appropriate risk management, in accordance with financial SOPs.

In my third year as Trustee, I have very much enjoyed working with the highly professional and efficient UKKA staff, receiving expert support from Stephanie Lock, Head of Finance & Business Development, and CEO Ron Cullen. I have also continued to champion the importance of basic science in improving the lives of people with kidney disease. Indeed, as a UK Kidney Week 2026 Co-Chair, I have worked alongside the UKKA's Hiedi Hutchinson, Rebecca Davies and Amy Robinson to ensure that once again the UK's leading annual conference for kidney health professionals and scientists has a vibrant discovery science component.

Financial Position and Reserves

The Trustees remain satisfied that the UKKA is in a secure financial position. The agreed reserves policy for 2025 sets a minimum level of £3 million and a maximum of £6 million, held either as liquid funds or in short- to medium-term investments. Reserves at the end of 2025 were £4.3 million (2024: £4.3 million), sufficient to cover 12 months of operating costs and to meet all liabilities when due. The trustees therefore confirm that the charity continues to be a going concern.



FINANCIAL REPORT

Income

Total income for 2025 was £6,731,999, an increase of 20% on the previous year (2024: £5,591,721). The largest contribution of income continues to come from capitation fees for the UK Renal Registry, which accounts for £2,752,896 (2024: £2,580,919). Membership income increased by 47%, following successful resolution of previous system issues and a movement to a tier-based offer. RaDaR project work continues to increase as awareness and utilisation of the database expands. Grant income increased to £501,000 (2024: £291,454), supported by new collaborative initiatives such as the Advanced Kidney Care programme and early CKD educational projects.

We also delivered and supported a significant programme of events during the year. UKKW 2025 was another highly successful conference, welcoming over 1,200 delegates to Bournemouth. Additional regional networking events and thematic summits were also delivered, with strong engagement from delegates and industry sponsors. Recognising the potential risk associated with UKKW 2026, due to its proximity to a major continental conference, we strategically planned to generate sufficient surplus in 2025 to mitigate any impact for the next year.

Expenditure


Total expenditure for 2025 was £5,875,887 (2024: £5,082,416), representing a 16% increase. Our staff costs increased significantly to £3,363,478 (2024: £2,773,698), reflecting employer NI increases and additional staffing required to deliver funded project work.

We had to invest funds into the infrastructure of our leased building, and we purchased a new membership system to resolve prior issues. Our meeting costs increased in line with the increased number of delegates at our events and expanded event activity.


The trustees have considered the Charity Commission's guidance on public benefit and confirm that all UKKA activities continue to align with our charitable aims.

Pie charts illustrating the UKKA's 2025 income and expenditure distribution are included below. For full details, please refer to the statutory accounts available via Companies House and the Charity Commission.





INCOME £6,731,999



EXPENDITURE £5,875,887

Disclaimer

The data reported here have been supplied by the UKKA, however the interpretation and reporting of the data are the responsibility of the author. The data is currently unaudited and therefore subject to change before the publication of the final accounts by September 2026.

Equality and diversity

The UK Kidney Association continues to be committed to creating and sustaining a positive, fair and mutually supportive environment. We accept, respect and value people with diverse identities and backgrounds and believe our differences make us stronger and more effective in achieving our goals. We ensure appointments are made on the recommendation of a transparent, balanced and appropriate panel, are made on the basis of merit, and encourage applications from all suitably qualified and eligible candidates.

Legal status

The Renal Association (trading as the UK Kidney Association) is registered in England and Wales as Company 2229663, limited by guarantee and registered as charity number 800733.

Articles and rules

You can read the articles and rules [here](#).



The UK Kidney Association
Brandon House, Building 20A1
Southmead Road
Bristol
BS34 7RR



ukka@ukkidney.org



ukkidney.org

2025